![Western blot - Anti-alpha Synuclein antibody [LB 509] (ab27766) image](#alpha-Synuclein-Primary-antibodies-ab27766-43.jpg)
Loading...
You have changed your country from
to
. Please be aware that this will change the currency in the purchasing process.
Products:Neuroscience >> Neurology process >> Neurodegenerative disease >> Parkinson's disease >> Synuclein
Overview
Product name
alpha Synuclein protein
See all alpha Synuclein products (21) ...
Protein description
Recombinant full length protein (Human)
Expression host
E. coli
Properties
Purity
>95% by SDS-PAGE
Form
Liquid
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage buffer
Preservative: None
Constituents: 0.1M Sodium chloride, 20mM Tris HCl, 1mM Magnesium chloride, pH 7.5
Concentration
Concentration information loading...
Sequence notes
MDVFMKGLSK / AKEGVVAAAE / KTKQGVAEAA / GKTKEGVLYV /GSKTKEGVV H/GVATVAEK TK/ EQVTNVGGAV /VTGVTAVAQ K/TVEGAGSI AA/ATGFVKK DQL/ GKNE EGAPQE/GIL EDMPVDP/DN EAYEMPSE/E GYQDYEPEA /
Research areas
Neuroscience >> Neurology process >> Neurodegenerative disease >> Alzheimer's disease >> Tangles & Tau
Neuroscience >> Neurology process >> Neurodegenerative disease >> Parkinson's disease >> Synuclein
Applications
Show applications key
Our Abpromise guarantee covers the use of ab51189 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: Use at an assay dependent concentration. (Ab51189 can be used as a WB positive control in conjunction with ab27766.)
SDS-PAGE: Use at an assay dependent dilution.
Protein info
Function
May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.
Tissue specificity
Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.
Involvement in disease
Note=Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1.
Defects in SNCA are the cause of Parkinson disease type 1 (PARK1) [MIM:168601]. A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.
Defects in SNCA are the cause of Parkinson disease type 4 (PARK4) [MIM:605543]. A complex neurodegenerative disorder with manifestations ranging from typical Parkinson disease to dementia with Lewy bodies. Clinical features include parkinsonian symptoms (tremor, rigidity, postural instability and bradykinesia), dementia, diffuse Lewy body pathology, autonomic dysfunction, hallucinations and paranoia.
Defects in SNCA are the cause of dementia Lewy body (DLB) [MIM:127750]. A neurodegenerative disorder clinically characterized by mental impairment leading to dementia, parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.
Sequence similarities
Belongs to the synuclein family.
Domain
The 'non A-beta component of Alzheimer disease amyloid plaque' domain (NAC domain) is involved in fibrils formation. The middle hydrophobic region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments.
Post-translational
modifications
Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress.
Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers.
Ubiquitinated. The predominant conjugate is the diubiquitinated form.
Cellular localization
Cytoplasm. Membrane. Nucleus. Cell junction > synapse. Membrane-bound in dopaminergic neurons.
Target information above from: UniProt accessionP37840
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
alpha Synuclein protein images:
Western blot - Anti-alpha Synuclein antibody [LB 509] (ab27766)
![Western blot - Anti-alpha Synuclein antibody [LB 509] (ab27766)](/ps/datasheet/images/27/ab27766/alpha-Synuclein-Primary-antibodies-ab27766-43.jpg)
Anti-alpha Synuclein antibody [LB 509] (ab27766) at 1/1000 dilution + alpha Synuclein protein (ab51189) at 0.1 µg
Secondary
Goat polyclonal Secondary Antibody to Mouse IgG - H&L (HRP), pre-adsorbed (ab97040) at 1/5000 dilution
developed using the ECL technique
Performed under reducing conditions.
Exposure time : 8 minutes
References for alpha Synuclein protein (ab51189)
ab51189 has not yet been referenced specifically in any publications.
Publishing research using ab51189? Please let us know so that we can cite the reference in this datasheet
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"